Enhanced educational activities around biosimilars are in the pipeline in the US, after the country’s Senate approved draft legislation that is set to bolster information available to healthcare professionals and patients.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?